Vaginal Microbiome Testing Market Report Scope & Overview:

The Vaginal Microbiome Testing Market was valued at USD 186.42 Million in 2025 and is expected to reach USD 452.18 Million by 2035, growing at a CAGR of 9.68% from 2026-2035.

The Vaginal Microbiome Testing Market will see traction due to growing awareness of women’s reproductive health, the high prevalence of bacterial vaginosis and other vaginal infections, and rapid advances in sequencing technology. Testing is moving beyond traditional methods such as Nugent scoring toward metagenomic sequencing panels that identify hundreds of bacteria and fungi from a single swab. Direct-to-consumer technology uses home sampling coupled with expert review and personalized care. In light of rising scientific interest in how vaginal microflora impact conception, pregnancies, and HPV, there is an increasing need for clinical testing. Alongside the unprecedented levels of investment into women’s health diagnostics, that drives rapid progress in the field.

⮞In September 2026, Evvy closed an oversubscribed USD 40 million Series B financing to expand its vaginal microbiome platform into reproductive healthcare, beginning with fertility and IVF. The company has served more than 100,000 patients and partnered with 3,000 practitioners using its at-home Vaginal Health Test.

U.S. Vaginal Microbiome Testing Market Outlook

The U.S. Vaginal Microbiome Testing Market was valued at USD 72.84 Million in 2025 and is expected to reach USD 176.32 Million by 2035, growing at a CAGR of 9.24% from 2026-2035.

The U.S. Vaginal Microbiome Testing Market is expanding owing to the high prevalence of bacterial vaginosis, strong consumer awareness of women’s health, and a well-developed direct-to-consumer testing ecosystem. Companies such as Evvy, Juno Bio, and MicroGenDX offer at-home sequencing tests supported by CLIA-certified laboratories and clinician review. Record investment in women’s health, which reached about USD 1.55 billion in equity funding in 2025, is also accelerating product development and commercial expansion across the country. Retail and pharmacy channels are also beginning to carry at-home kits.

⮞In July 2026, Juno Bio raised USD 3.8 million to open its first CLIA-certified sequencing laboratory in Oakland, California, and launch a clinically actionable vaginal microbiome and STI test. The at-home test analyzes around 10,000 bacteria and fungi alongside four common sexually transmitted infections.

By Type, Test Kits Lead and Grow Fastest

Test kits dominate the Vaginal Microbiome Testing Market in 2025 and will be the fastest growing mode in the coming years because kits form the main mode of delivery in both clinical and home-based vaginal microbiome testing. Test kit is made up of a swab, transport medium, and prepaid shipping to a certified lab. Options such as Evvy Vaginal Health Test and Juno Bio’s at-home test have increased accessibility to tests without visiting clinics. Subscription models where women test every three months to track changes have increased repeat business in the market. With decreasing costs of test kits, more people are able to afford them.

Instruments represent a smaller share, covering the sequencers, PCR analyzers, and automated sample preparation systems used in laboratories that process vaginal samples. Instrument demand grows more slowly because a single sequencer can process large sample volumes, so purchases are less frequent than consumable kits. However, vertical integration by testing companies opening their own laboratories, such as Juno Bio’s new sequencing facility, is creating fresh instrument demand as providers bring analysis capability in house. Laboratory automation suppliers also benefit from this shift toward vertical integration.

⮞In October 2026, UK-based Daye launched its Vaginal Microbiome Screening service, offering home-based screening kits designed to assess risks associated with vaginal infections, sexually transmitted infections, and fertility complications, expanding consumer access to vaginal health testing.

By Technology, PCR Leads, While Next-Generation Sequencing Grows Fastest

PCR-based tests dominated the Vaginal Microbiome Testing Market in 2025 due to their reliable, rapid, and cost-effective identification of pathogens associated with bacterial vaginosis (BV) using real-time PCR panels. These tests detect key microorganisms, including Gardnerella vaginalis, Fannyhessea vaginae, and Lactobacillus species, offering improved diagnostic reliability compared with traditional Nugent scoring methods. Their ability to provide consistent results supports clinical decision-making and timely treatment. Additionally, established laboratory workflows, favorable reimbursement policies, and clinician preference for molecular diagnostic techniques strengthen the segment’s revenue contribution. These factors collectively reinforce PCR-based testing as the leading technology in the Vaginal Microbiome Testing Market.

Next-generation sequencing is the fastest-growing technology, as metagenomic approaches identify hundreds of bacteria and fungi rather than a predefined target list. Evvy’s test analyzes more than 700 organisms, while Juno Bio’s platform covers roughly 10,000, giving a far more complete picture of microbial balance. Sequencing has enabled new discoveries, including the identification of additional bacterial vaginosis subtypes and previously uncatalogued vaginal genomes. Falling sequencing costs, growing bioinformatics capability, and AI platforms trained on large proprietary datasets are making these tests more affordable and clinically useful, supporting rapid segment growth. Growing published evidence is also strengthening clinician confidence in sequencing results.

⮞In December 2025, Roche announced CE marking for its cobas® BV/CV assay, a PCR-based diagnostic that identifies bacteria associated with bacterial vaginosis and Candida species linked to vaginal candidiasis from a single sample, expanding molecular testing options for symptomatic patients.

By End User, Hospitals & Clinics Lead, While Home Settings Grow Fastest

Hospitals and Clinics were the Dominant Segment in the Vaginal Microbiome Testing Market in 2025, as majority of orders for the test are generated from gynecologists, family practitioners, and sexual health centers. Clinical testing centers cater to the symptomatic testing, pregnancy testing, and prescription based testing, all with proper avenues for reimbursement. High throughput molecular panels using automated instruments are used by hospitals and reference labs with large test menus at cost-effective pricing. Awareness among clinicians regarding the shortcomings of traditional diagnostic tests will lead to the increasing adoption of molecular testing, thus aiding in maintaining the leadership of this segment during the forecast period.

Home settings represent the fastest-growing end user segment, driven by consumer demand for privacy, convenience, and faster answers than a clinic visit allows. Self-collected vaginal swabs have shown accuracy comparable to clinician-collected samples, supporting clinical confidence in at-home testing. Telehealth platforms combine virtual consultations with sample kits and prescription treatment, closing the loop between diagnosis and care. Company data suggests many women have been misdiagnosed through standard care, which is driving interest in direct-access testing. Subscription models and growing retail availability are expected to sustain very strong growth in this segment. Faster turnaround times further improve the overall patient experience.

⮞In October 2026, bioMérieux received U.S. FDA 510(k) clearance and a CLIA waiver for its BIOFIRE® SPOTFIRE® Vaginitis Panel, enabling automated multiplex PCR testing for common causes of vaginitis in approximately 20 minutes at the point of care.

Regional Analysis

North America Vaginal Microbiome Testing Market Insights

North America accounted for approximately 43.62% of the Vaginal Microbiome Testing Market in 2025, the largest share among all regions, supported by advanced research infrastructure, high awareness of women’s health, and a mature direct-to-consumer testing ecosystem. The United States generates most regional revenue, with companies including Evvy, Juno Bio, and MicroGenDX offering clinical and at-home tests. High bacterial vaginosis prevalence and growing frustration with traditional diagnostic methods are driving demand. Record equity investment in women’s health is also accelerating product development and commercial expansion across the region. Strong clinical research activity further supports regional adoption.

Canada contributes a growing share, supported by public health initiatives such as the Healthy Pregnancy Hub under the Pan-Canadian Women’s Health Coalition, which promotes reliable information about infections during pregnancy. Mexico represents an emerging market, where private laboratory networks are expanding access to molecular women’s health testing. Across the region, telehealth adoption is making testing and prescription treatment more convenient, while vertical integration by testing companies opening their own CLIA laboratories is improving turnaround times. However, limited insurance coverage for consumer-directed microbiome tests continues to restrict broader adoption among price-sensitive patients. Employer health benefits may gradually improve affordability for some women.

⮞In September 2026, Good Clean Clinical Care launched a microbiome-focused telehealth platform combining vaginal microbiome testing, specialist consultations, and personalized treatment services, expanding the integration of consumer-accessible diagnostics with clinician-led women's healthcare.

Europe Vaginal Microbiome Testing Market Insights

Europe continues to be the second-largest regional market, supported by the United Kingdom, Germany, France, Italy, and Spain, where public healthcare systems and established gynecology services provide broad access to diagnostic testing. The region hosts several women’s health testing innovators, including Juno Bio and Daye in the United Kingdom, which offer at-home vaginal microbiome and screening products. European research groups have contributed significantly to understanding of vaginal microbiota composition. The European In Vitro Diagnostic Regulation has raised clinical evidence requirements, favoring suppliers with strong validation data and established quality systems. National screening programs also help support consistent clinical testing volumes.

The United Kingdom is one of the leaders of regional innovation, where femtech startups integrate microbiome testing with clinical pathways and NHS sexual health services are gradually integrating molecular diagnostics. The German market drives demand due to the country’s large lab segment and diagnostics industry, France, Italy, and Spain drive demand due to their hospital laboratories and private testing landscape. Rising awareness of the association between vaginal health and pregnancy is further driving demand. However, low reimbursement for consumer microbiome tests continues to hinder adoption in multiple European countries, leaving private clinics as the main channel for such tests.

⮞In August 2025, the UK's Medicines and Healthcare products Regulatory Agency published a review highlighting the potential of vaginal microbiome diagnostics for earlier and more personalized assessment of infections, infertility, pregnancy complications, and other women's health conditions.

Asia-Pacific Vaginal Microbiome Testing Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Vaginal Microbiome Testing Market, anticipated to record a CAGR of around 11.58% during the forecast period from 2026 to 2035, driven by a large female population, rising healthcare spending, and growing awareness of reproductive health. China is the largest market in the region, supported by expanding gynecology services, growing private healthcare capacity, and strong domestic molecular diagnostics manufacturers. Government focus on maternal and women’s health, together with rising disposable incomes in urban areas, is increasing the number of women accessing advanced diagnostic testing. Online health platforms are also expanding consumer access across major cities.

Japan and South Korea contribute through advanced laboratory infrastructure, high diagnostic standards, and growing consumer interest in personalized health testing. India is emerging as a key growth market, supported by a large undiagnosed patient population, rapid expansion of private diagnostic chains, and increasing adoption of molecular testing in metropolitan centers. Australia supports demand through strong sexual health services and active microbiome research. Growing e-commerce penetration is also making at-home testing kits more accessible across the region, which is expected to support strong market growth over the forecast period. Local manufacturing may further improve overall affordability across these price-sensitive regional markets.

⮞In December 2025, China's Uni-Medica obtained a Class II medical device registration certificate for its vaginal microbiota immunofluorescence detection kit, designed to work with compatible fluorescent scanning and image-analysis systems to support the assessment of vaginal inflammation.

MEA & Latin America Vaginal Microbiome Testing Market Insights

The Middle East & Africa region represents a smaller but developing share of the Vaginal Microbiome Testing Market, led by Gulf Cooperation Council states such as Saudi Arabia and the UAE, which are investing in modern hospital laboratories and specialized women’s health services. Expanding health insurance coverage and government healthcare transformation programs are improving access to molecular diagnostics. Sub-Saharan Africa carries a high burden of bacterial vaginosis, and its link to higher HIV acquisition risk is increasing research interest in affordable screening. However, limited laboratory infrastructure and cultural barriers restrict testing uptake across much of the region. Donor-funded programs may gradually improve access.

Latin America is experiencing steady growth, with Brazil leading the region through its large female population, broad public healthcare system, and established network of private diagnostic laboratories. Mexico and Argentina contribute demand through expanding hospital laboratories and growing gynecology practices. Rising awareness of links between vaginal infections and pregnancy complications is supporting wider screening. Private laboratory chains are gradually adding molecular vaginitis panels to their women’s health menus. However, limited reimbursement for advanced testing, lower consumer purchasing power, and continued reliance on empiric treatment restrict faster market growth across the region. Growing telehealth adoption may gradually improve testing access for many women.

Market Dynamics

Growth Drivers: Rising Women’s Health Awareness and Sequencing Advances

The growth of the Vaginal Microbiome Testing market can be attributed to the rising awareness of the health of women and the prevalence of vaginal infections. Conditions such as bacterial vaginosis, yeast infections, and trichomoniasis are very common in women of reproductive age; a significant proportion suffers from recurrent symptoms. The work carried out by International Society for the Study of Vulvovaginal Disease on raising awareness regarding vaginal health is contributing to the growth of this field. According to studies, a significant number of patients are wrongly diagnosed in conventional settings, thus, leading to high demands for more accurate tests which will diagnose the specific microorganism. Recurrent symptoms lead to repeat testing.

New developments in sequencing and molecular technology are driving growth in this field. The sequencing of the metagenome allows to detect hundreds or even thousands of microorganisms through one swab, which is much better than traditional microscopy or culture techniques. The studies show that real-time PCR panels have very good accuracy compared with Nugent scoring in classification of unclear cases. As the cost of the sequencing becomes lower and bioinformatics better, these tests become less expensive. More researches on vaginal microbiome and its relation to fertility, success rate of IVF, preterm birth and HPV progression widen the use of these tests in clinical settings.

⮞In May 2026, Japan's UMIN Clinical Trials Registry disclosed the HORAC-VAGI trial, a randomized controlled study evaluating a Lactobacillus-based oral formulation for vaginal microbiome restoration in women with unexplained infertility, reflecting continued clinical investigation of reproductive-health applications.

Restraints: High Testing Costs and Limited Clinical Evidence

The high cost of microbiome testing remains a key factor limiting market growth. At-home sequencing tests typically cost between USD 100 and USD 160 per test, and most are not covered by insurance, requiring patients to pay out of pocket. Subscription models reduce the per-test price but still represent meaningful ongoing expense. In many countries, reimbursement for consumer-directed microbiome testing is limited or absent, restricting adoption among price-sensitive patients. These costs are particularly significant in emerging markets, where a large share of the affected population has limited healthcare spending capacity. Public health budgets also rarely cover these newer diagnostic tests.

Further limitations exist due to controversies around clinical evidence, whereby there are certain clinicians who argue that the microbiome profiling does not impact the way of treatment beyond what is provided by the existing diagnostic tools. The interpretation of the test is difficult, as the normal vaginal microbiome varies greatly in different individuals and ethnic populations. There is growing regulatory pressure regarding health claims made by the companies, making it necessary for them to prove and interpret their tests properly. Further, due to lack of standardization between the platforms used in sequencing and reporting, it is difficult to compare the results of the tests. Culture-sensitive vaginal health issues also discourage many women from testing in some areas.

Opportunities: Fertility Applications and Emerging Market Expansion

The expansion of vaginal microbiome testing into fertility and reproductive care creates a significant opportunity for the market. Evvy is running prospective studies with IVF clinics to evaluate whether microbiome profiles can predict treatment outcomes, building on peer-reviewed research and studies covering more than 1,000 patients. Potential applications extend to preterm birth risk, endometriosis, perimenopause, and HPV progression. Companies that generate strong clinical evidence linking microbiome data to outcomes can secure clinical adoption and potential reimbursement, moving testing from consumer wellness toward established reproductive healthcare practice. Partnerships with fertility clinics can also meaningfully accelerate this ongoing shift toward clinical adoption.

At the same time, emerging markets and new care models provide major growth opportunities. Rising healthcare spending, growing e-commerce penetration, and expanding private diagnostic networks across Asia-Pacific and Latin America are improving access to testing. Telehealth platforms that combine virtual consultation, at-home sampling, and prescription treatment can reach women who avoid clinic visits. AI platforms built on large proprietary datasets, such as EvvyAI, can improve interpretation and personalize treatment recommendations. Partnerships with fertility clinics, gynecology networks, and retail pharmacy chains can further widen distribution and build clinical credibility. Strong clinical validation remains essential to support this planned commercial expansion into reproductive care.

⮞In May 2026, Osel Inc., March of Dimes, and Imperial Clinical Trials Unit announced the FLIP-2 Phase 2b trial of LACTIN-V, a live biotherapeutic containing Lactobacillus crispatus, to evaluate its safety and efficacy for preventing preterm birth in high-risk pregnancies, advancing investigation of vaginal microbiome interventions in maternal health.

Vaginal Microbiome Testing Market Key Players

• Evvy

• Juno Bio

• Tiny Health

• MicroGenDX

• Daye

Vaginal Microbiome Testing Market Report Scope: